Product image of Hepatect (Human Hepatitis B Immunoglobulin) supplied by GNH India

Hepatect

Active Ingredient:
Human Hepatitis B Immunoglobulin
Origin:
EU

Hepatect (Human Hepatitis B Immunoglobulin)

Hepatect is a human hepatitis B immunoglobulin supplied as a solution for injection. The product contains purified anti‑hepatitis B surface antigen antibodies, with strength not specified, and is administered intravenously. It is classified as an immunoglobulin (HBIG) and is available by prescription in the European Union for passive immunization against hepatitis B virus.

Manufacturer / TM Owner

Biotest Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Hepatect is used to provide passive immunity against hepatitis B virus in specific clinical situations.

  • Post‑exposure prophylaxis for individuals with potential hepatitis B exposure who have not completed vaccination.
  • Prevention of hepatitis B recurrence after orthotopic liver transplantation.
  • Protection of patients with chronic liver disease who are undergoing immunosuppressive therapy.
  • Adjunctive prophylaxis in newborns of hepatitis B‑positive mothers when vaccine response is inadequate.
  • Supplementation for individuals with inadequate response to hepatitis B vaccine series.

Side Effects

Adverse reactions to Hepatect are generally mild to moderate, but serious events can occur.

Common

  • Injection site discomfort or erythema.
  • Mild fever or chills following administration.
  • Headache or fatigue within 24 hours.

Serious

  • Anaphylactic or severe allergic reactions, including urticaria and bronchospasm.
  • Acute hemolysis or transfusion‑related acute lung injury (TRALI).
  • Severe hypotension or cardiovascular collapse.

Precautions & Warnings

Healthcare providers should consider several precautions when prescribing Hepatect.

  • Assess patient history for prior allergic reactions to blood products or immunoglobulins.
  • Monitor vital signs during and after infusion, especially in patients with cardiovascular disease.
  • Use caution in pregnant or breastfeeding individuals; safety data are limited.
  • Adjust dosing in patients with renal impairment, as clearance may be reduced.
  • Ensure hepatitis B surface antigen status is confirmed before administration.
  • Document any adverse events and report serious reactions to pharmacovigilance authorities.

Avoid Interactions

Hepatect may interact with other agents, requiring careful management.

Avoid

  • Concurrent administration of other immunoglobulin products that could increase the risk of hyperviscosity.
  • Live vaccines administered within 4 weeks of Hepatect, as passive antibodies may interfere with vaccine efficacy.

Use with caution

  • Anticoagulants, because infusion may affect coagulation parameters.
  • Immunosuppressive drugs, which could alter the duration of passive immunity.
  • High‑dose steroids, potentially affecting antibody metabolism.
  • Renal‑clearing drugs, as volume load from infusion may impact renal function.

Frequently Asked Questions

Hepatect provides passive immunity by delivering anti‑hepatitis B surface antigen antibodies that bind to HBV, neutralizing the virus and preventing it from infecting liver cells.

It is indicated for individuals who have been exposed to hepatitis B virus and have not completed the full hepatitis B vaccination series or have an inadequate vaccine response.

Yes, Hepatect may be administered to newborns when passive immunization is needed in addition to the hepatitis B vaccine, especially if the infant’s vaccine response is uncertain.

Common side effects include mild fever, chills, headache, fatigue, and local injection site discomfort or redness.

Serious reactions can include anaphylaxis, severe allergic responses, acute hemolysis, transfusion‑related acute lung injury, and significant hypotension.

Safety data in pregnancy are limited; the product should be used only if the potential benefit justifies the potential risk to the fetus.

Hepatect is given as an intravenous infusion under medical supervision, with monitoring of vital signs during and after the infusion.

Patients with reduced kidney function may require dose adjustment and close monitoring of fluid balance due to the volume of the infusion.

Live vaccines should be avoided for at least four weeks after Hepatect administration because passive antibodies can diminish vaccine effectiveness.

The infusion should be stopped immediately, and appropriate emergency treatment, such as antihistamines, epinephrine, and supportive care, should be provided.

No, Hepatect is a prescription‑only medication and must be prescribed by a qualified healthcare professional.

Patients should be observed for signs of allergic reaction, vital sign changes, and any unexpected symptoms for at least 30 minutes post‑infusion.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Hepatitis B Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT